BIO Ventures for Global Health Launches New Online Tool

Global Health Primer by Disease

This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development. The Primer identifies gaps in the product pipeline for these diseases helping to highlight areas where companies and others can add effort and make the most progress. Content for the tool includes:

  • Creation of drug target and vaccine technology profiles in addition to the neglected disease profiles. These profiles group products in development by drug target classes and vaccine technologies that may span multiple diseases.
  • Expansion of each disease profile to include drug target and vaccine technology analysis that spotlights opportunities for application to neglected tropical diseases.
  • Greater analysis of strengths, weaknesses, opportunities, and risks for products currently in development for neglected tropical diseases, as well as information on development tools that are available to facilitate new product development

Click here to check out the Global Health Primer for TB

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...